O	0	10	Expression	Expression	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	23	epidermal	epidermal	JJ	B-NP
O	24	30	growth	growth	NN	I-NP
O	31	37	factor	factor	NN	I-NP
O	38	46	receptor	receptor	NN	I-NP
O	46	47	,	,	,	O
O	48	60	transforming	transform	VBG	B-VP
O	61	67	growth	growth	NN	B-NP
O	68	74	factor	factor	NN	I-NP
O	74	75	-	-	HYPH	O
O	75	80	alpha	alpha	SYM	B-NP
O	81	84	and	and	CC	O
O	85	87	Ki	Ki	NN	B-NP
O	87	88	-	-	HYPH	O
O	88	90	67	67	CD	B-NP
O	91	93	in	in	IN	B-PP
O	94	106	relationship	relationship	NN	B-NP
O	107	109	to	to	TO	B-PP
O	110	119	malignant	malignant	JJ	B-NP
O	120	134	transformation	transformation	NN	I-NP
O	135	137	of	of	IN	B-PP
B-Pathological_formation	138	149	pleomorphic	pleomorphic	JJ	B-NP
I-Pathological_formation	150	157	adenoma	adenoma	NN	I-NP
O	157	158	.	.	.	O

O	160	170	CONCLUSION	CONCLUSION	NN	B-NP
O	170	171	:	:	:	O
O	172	184	Quantitative	Quantitative	JJ	B-NP
O	185	195	assessment	assessment	NN	I-NP
O	196	198	is	be	VBZ	B-VP
O	199	203	more	more	RBR	B-ADJP
O	204	213	sensitive	sensitive	JJ	I-ADJP
O	214	216	as	as	IN	B-PP
O	217	218	a	a	DT	B-NP
O	219	226	measure	measure	NN	I-NP
O	227	229	of	of	IN	B-PP
B-Cell	230	238	cellular	cellular	JJ	B-NP
O	239	246	protein	protein	NN	I-NP
O	247	254	content	content	NN	I-NP
O	255	257	as	as	IN	B-PP
O	258	266	compared	compare	VBN	B-PP
O	267	271	with	with	IN	B-PP
O	272	280	standard	standard	JJ	B-NP
O	281	288	optical	optical	JJ	I-NP
O	289	296	density	density	NN	I-NP
O	297	309	measurements	measurement	NNS	I-NP
O	309	310	.	.	.	O

O	311	314	The	The	DT	B-NP
O	315	319	data	datum	NNS	I-NP
O	320	327	support	support	VBP	B-VP
O	328	331	the	the	DT	B-NP
O	332	342	hypothesis	hypothesis	NN	I-NP
O	343	347	that	that	IN	B-SBAR
O	348	357	increased	increase	VBN	B-NP
O	358	367	epidermal	epidermal	JJ	I-NP
O	368	374	growth	growth	NN	I-NP
O	375	381	factor	factor	NN	I-NP
O	382	390	receptor	receptor	NN	I-NP
O	391	392	(	(	(	O
O	392	396	EGFR	EGFR	NN	B-NP
O	396	397	)	)	)	O
O	398	401	and	and	CC	O
O	402	414	transforming	transform	VBG	B-VP
O	415	421	growth	growth	NN	B-NP
O	422	428	factor	factor	NN	I-NP
O	429	430	(	(	(	O
O	430	433	TGF	TGF	NN	B-NP
O	433	434	)	)	)	O
O	434	435	-	-	HYPH	B-NP
O	435	440	alpha	alpha	NN	I-NP
O	441	451	expression	expression	NN	I-NP
O	452	454	is	be	VBZ	B-VP
O	455	465	associated	associate	VBN	I-VP
O	466	470	with	with	IN	B-PP
O	471	476	early	early	JJ	B-NP
O	477	483	events	event	NNS	I-NP
O	484	486	in	in	IN	B-PP
O	487	496	malignant	malignant	JJ	B-NP
O	497	511	transformation	transformation	NN	I-NP
O	512	514	of	of	IN	B-PP
B-Pathological_formation	515	526	pleomorphic	pleomorphic	JJ	B-NP
I-Pathological_formation	527	534	adenoma	adenoma	NN	I-NP
O	535	536	(	(	(	O
B-Pathological_formation	536	538	PA	PA	NN	B-NP
O	538	539	)	)	)	O
O	539	540	.	.	.	O

O	541	550	OBJECTIVE	OBJECTIVE	NN	B-NP
O	550	551	:	:	:	O
O	552	554	In	In	IN	B-PP
O	555	558	the	the	DT	B-NP
O	559	566	present	present	JJ	I-NP
O	567	572	study	study	NN	I-NP
O	572	573	,	,	,	O
O	574	576	we	we	PRP	B-NP
O	577	586	attempted	attempt	VBD	B-VP
O	587	589	to	to	TO	I-VP
O	590	598	identify	identify	VB	I-VP
O	599	603	EGFR	EGFR	NN	B-NP
O	604	607	and	and	CC	I-NP
O	608	611	TGF	TGF	NN	I-NP
O	611	612	-	-	HYPH	O
O	612	617	alpha	alpha	SYM	B-NP
O	618	628	expression	expression	NN	B-NP
O	629	632	and	and	CC	O
O	633	635	Ki	Ki	NN	B-NP
O	635	636	-	-	HYPH	O
O	636	638	67	67	CD	B-NP
O	639	644	index	index	NN	I-NP
O	645	647	in	in	IN	B-PP
B-Cancer	648	657	carcinoma	carcinoma	NN	B-NP
I-Cancer	658	660	ex	ex	NN	I-NP
I-Cancer	660	661	-	-	HYPH	B-NP
I-Cancer	661	672	pleomorphic	pleomorphic	JJ	I-NP
I-Cancer	673	680	adenoma	adenoma	NN	I-NP
O	681	682	(	(	(	O
B-Cancer	682	684	Ca	Ca	NN	B-NP
I-Cancer	685	687	ex	ex	NN	I-NP
I-Cancer	687	688	-	-	HYPH	B-NP
I-Cancer	688	690	PA	PA	NN	I-NP
O	690	691	)	)	)	O
O	692	695	and	and	CC	O
B-Pathological_formation	696	698	PA	PA	NN	B-NP
O	698	699	.	.	.	O

O	700	702	We	We	PRP	B-NP
O	703	707	also	also	RB	B-ADVP
O	708	716	compared	compare	VBD	B-VP
O	717	720	the	the	DT	B-NP
O	721	729	presence	presence	NN	I-NP
O	730	732	of	of	IN	B-PP
O	733	737	EGFR	EGFR	NN	B-NP
O	738	741	and	and	CC	I-NP
O	742	745	TGF	TGF	NN	I-NP
O	745	746	-	-	HYPH	O
O	746	751	alpha	alpha	SYM	B-NP
O	752	755	and	and	CC	O
O	756	758	Ki	Ki	NN	B-NP
O	758	759	-	-	HYPH	O
O	759	761	67	67	CD	B-NP
O	762	767	index	index	NN	I-NP
O	768	772	with	with	IN	B-PP
O	773	781	clinical	clinical	JJ	B-NP
O	782	786	data	datum	NNS	I-NP
O	786	787	.	.	.	O

O	788	797	MATERIALS	MATERIALS	NNS	B-NP
O	798	801	AND	AND	CC	I-NP
O	802	809	METHODS	METHODS	NNS	I-NP
O	809	810	:	:	:	O
O	811	814	The	The	DT	B-NP
B-Tissue	815	822	tissues	tissue	NNS	I-NP
O	823	827	were	be	VBD	B-VP
O	828	835	stained	stain	VBN	I-VP
O	836	840	with	with	IN	B-PP
O	841	851	monoclonal	monoclonal	JJ	B-NP
O	852	862	antibodies	antibody	NNS	I-NP
O	863	865	to	to	TO	B-PP
O	866	870	EGFR	EGFR	NN	B-NP
O	870	871	,	,	,	O
O	872	875	TGF	TGF	NN	B-NP
O	875	876	-	-	HYPH	O
O	876	881	alpha	alpha	SYM	B-NP
O	882	885	and	and	CC	O
O	886	888	Ki	Ki	NN	B-NP
O	888	889	-	-	SYM	O
O	889	891	67	67	CD	B-NP
O	891	892	.	.	.	O

O	893	896	The	The	DT	B-NP
O	897	904	results	result	NNS	I-NP
O	905	909	were	be	VBD	B-VP
O	910	918	analysed	analyse	VBN	I-VP
O	919	924	using	use	VBG	B-VP
O	925	937	quantitative	quantitative	JJ	B-NP
O	938	957	immunohistochemical	immunohistochemical	JJ	I-NP
O	958	966	analysis	analysis	NN	I-NP
O	966	967	.	.	.	O

O	968	970	We	We	PRP	B-NP
O	971	975	also	also	RB	B-ADVP
O	976	984	analysed	analyse	VBD	B-VP
O	985	988	the	the	DT	B-NP
O	989	1000	association	association	NN	I-NP
O	1001	1003	of	of	IN	B-PP
O	1004	1012	patients	patient	NNS	B-NP
O	1012	1013	'	'	POS	B-NP
O	1014	1023	prognosis	prognosis	NN	I-NP
O	1024	1028	with	with	IN	B-PP
O	1029	1037	clinical	clinical	JJ	B-NP
O	1038	1048	parameters	parameter	NNS	I-NP
O	1049	1052	and	and	CC	O
O	1053	1056	the	the	DT	B-NP
O	1057	1069	histological	histological	JJ	I-NP
O	1070	1084	classification	classification	NN	I-NP
O	1085	1087	of	of	IN	B-PP
O	1088	1091	the	the	DT	B-NP
B-Cancer	1092	1105	carcinomatous	carcinomatous	JJ	I-NP
I-Cancer	1106	1115	component	component	NN	I-NP
O	1115	1116	.	.	.	O

O	1117	1124	RESULTS	RESULTS	NNS	B-NP
O	1124	1125	:	:	:	O
O	1126	1128	As	As	IN	B-SBAR
O	1129	1136	regards	regard	VBZ	B-VP
O	1137	1140	the	the	DT	B-NP
O	1141	1152	association	association	NN	I-NP
O	1153	1155	of	of	IN	B-PP
O	1156	1164	patients	patient	NNS	B-NP
O	1164	1165	'	'	POS	B-NP
O	1166	1175	prognosis	prognosis	NN	I-NP
O	1176	1180	with	with	IN	B-PP
O	1181	1185	EGFR	EGFR	NN	B-NP
O	1186	1194	staining	staining	NN	I-NP
O	1195	1198	and	and	CC	I-NP
O	1199	1201	Ki	Ki	NN	I-NP
O	1201	1202	-	-	HYPH	B-NP
O	1202	1204	67	67	CD	I-NP
O	1205	1210	index	index	NN	I-NP
O	1210	1211	,	,	,	O
O	1212	1213	a	a	DT	B-NP
O	1214	1225	significant	significant	JJ	I-NP
O	1226	1234	increase	increase	NN	I-NP
O	1235	1238	was	be	VBD	B-VP
O	1239	1247	observed	observe	VBN	I-VP
O	1248	1250	in	in	IN	B-PP
O	1251	1259	patients	patient	NNS	B-NP
O	1260	1263	who	who	WP	B-NP
O	1264	1268	died	die	VBD	B-VP
O	1269	1271	or	or	CC	I-VP
O	1272	1275	had	have	VBD	I-VP
O	1276	1284	residual	residual	JJ	B-NP
O	1285	1292	disease	disease	NN	I-NP
O	1293	1301	compared	compare	VBN	B-PP
O	1302	1306	with	with	IN	B-PP
O	1307	1315	patients	patient	NNS	B-NP
O	1316	1319	who	who	WP	B-NP
O	1320	1324	were	be	VBD	B-VP
O	1325	1330	alive	alive	JJ	B-ADJP
O	1331	1338	without	without	IN	B-PP
O	1339	1346	disease	disease	NN	B-NP
O	1346	1347	.	.	.	O

O	1348	1350	In	In	IN	B-PP
O	1351	1354	the	the	DT	B-NP
O	1355	1374	immunohistochemical	immunohistochemical	JJ	I-NP
O	1375	1383	analysis	analysis	NN	I-NP
O	1384	1386	of	of	IN	B-PP
O	1387	1391	EGFR	EGFR	NN	B-NP
O	1392	1395	and	and	CC	I-NP
O	1396	1399	TGF	TGF	NN	I-NP
O	1399	1400	-	-	HYPH	O
O	1400	1405	alpha	alpha	SYM	B-NP
O	1406	1409	and	and	CC	O
O	1410	1414	Ki67	Ki67	NN	B-NP
O	1415	1420	index	index	NN	I-NP
O	1420	1421	,	,	,	O
O	1422	1423	a	a	DT	B-NP
O	1424	1435	significant	significant	JJ	I-NP
O	1436	1444	increase	increase	NN	I-NP
O	1445	1448	was	be	VBD	B-VP
O	1449	1457	observed	observe	VBN	I-VP
O	1458	1460	in	in	IN	B-PP
B-Cancer	1461	1463	Ca	Ca	NN	B-NP
I-Cancer	1464	1466	ex	ex	NN	I-NP
I-Cancer	1466	1467	-	-	HYPH	B-NP
I-Cancer	1467	1469	PA	PA	NN	I-NP
O	1469	1470	,	,	,	O
O	1471	1481	especially	especially	RB	B-ADVP
O	1482	1486	with	with	IN	B-PP
B-Cancer	1487	1501	adenocarcinoma	adenocarcinoma	NN	B-NP
O	1501	1502	,	,	,	O
O	1503	1511	compared	compare	VBN	B-PP
O	1512	1516	with	with	IN	B-PP
B-Pathological_formation	1517	1519	PA	PA	NN	B-NP
O	1520	1523	and	and	CC	I-NP
O	1524	1536	sialadenitis	sialadenitis	NN	I-NP
O	1536	1537	.	.	.	O

